GenPath logo in conjunction with oncology

Hereditary Cancer Testing

Through GenPath’s collaboration with sister company, GeneDx, our laboratory offers comprehensive panels to test key genes associated with increased susceptibility to many cancer sub-types.

With high quality testing, expertise, and experience, GeneDx has performed over 184,000 hereditary cancer tests to date.

GeneDx Is A Pioneer In The Inherited Disorders Industry

  • GeneDx was the first to commercially launch next-generation sequencing (NGS) in 2008
  • GeneDx co-founders are thought-leaders and are co-authors of established guidelines, such as the ACMG guidelines on NGS

GeneDx Development Timeline

GenPath Hereditary Cancer Panels Provide Accurate Results With Industry-Leading Turn-Around Times

View test options for hereditary cancer panels

*Testing includes sequencing and deletion duplication for all genes except EPCAM (del/dup only),
MITF (evaluation of c.952G>A only), and SCG5/GREM1 (del/dup only).

See a complete list of hereditary cancer panels offered by GeneDx.

©2019 GenPath, a division of BioReference Laboratories Inc., an OPKO Health Company